BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15975521)

  • 1. A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma.
    Chua DT; Sham JS; Au GK
    Oral Oncol; 2005 Jul; 41(6):589-95. PubMed ID: 15975521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer.
    Bae WK; Hwang JE; Shim HJ; Cho SH; Lee JK; Lim SC; Chung WK; Chung IJ
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):589-95. PubMed ID: 19830427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Azli N; Fandi A; Bachouchi M; Rahal M; Lianes P; Wibault P; Boussen H; Eschwege F; Armand JP; Cvitkovic E
    Cancer J Sci Am; 1995; 1(3):222-9. PubMed ID: 9166480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).
    Ji JH; ; Yun T; Kim SB; Kang JH; Park JC; Cho IS; Sohn CH; Heo DS; Jang JS; Shin SW; Hwang DW; Sun JM; Park K; Ahn MJ
    Eur J Cancer; 2012 Nov; 48(17):3198-204. PubMed ID: 22795584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer.
    Shamseddine AI; Otrock ZK; Khalifeh MJ; Yassine HR; Charafeddine M; Abdel-Khalek Z; Chehal A; Bitar N; Jalloul R; Dheiny M; Dandashi A; Wehbeh M; El-Saghir NS
    Oncology; 2006; 70(5):330-8. PubMed ID: 17164589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
    Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
    Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
    Kourousis C; Androulakis N; Kakolyris S; Souglakos J; Maltezakis G; Metaxaris G; Chalkiadakis G; Samonis G; Vlachonikolis J; Georgoulias V
    Cancer; 1998 Nov; 83(10):2083-90. PubMed ID: 9827712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.
    Li YH; Wang FH; Jiang WQ; Xiang XJ; Deng YM; Hu GQ; Xu DM; Chen Y; Lin Q; He YJ
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):539-44. PubMed ID: 18172651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
    Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
    Michalaki V; Gennatas S; Gennatas K
    Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
    Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin.
    Polyzos A; Tsavaris N; Kosmas C; Polyzos K; Giannopoulos A; Felekouras E; Nikiteas N; Kouraklis G; Griniatsos J; Safioleas M; Stamatakos M; Pikoulis E; Papachristodoulou A; Gogas H
    Anticancer Res; 2006; 26(5B):3749-53. PubMed ID: 17094396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
    Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer.
    Le Chevalier T; Bérille J; Zalcberg JR; Millward MJ; Monnier A; Douillard JY; McKeage MJ; James R; Soulas F; Loret C; Bougon N; Bizzari JP
    Semin Oncol; 1999 Jun; 26(3 Suppl 11):13-8. PubMed ID: 10458205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.